Thyroid Gland Papillary Carcinoma

Given oncologic necessity, selpercatinib was reintroduced at a reduced dose (40 mg daily) without recurrence of severe transaminitis. This case highlights that selpercatinib can cause clinically significant hepatocellular DILI and underscores the diagnostic value of liver biopsy in distinguishing DILI from autoimmune hepatitis, particularly when considering safe dose modification and rechallenge.

This study identified that CHI3L1 was an oncogene in PTC and promotes tumor cell proliferation associated with downregulating the TP53 pathway. It provides new evidence supporting CHI3L1 as a potential molecular target for future therapeutic investigation in PTC.

P2, N=25, Recruiting, Istituti Clinici Scientifici Maugeri SpA | Trial completion date: Dec 2027 --> Nov 2026

Because they require standardized gene-expression inputs and have not undergone prospective clinical validation, they should not be used as standalone tools for clinical diagnosis, risk stratification, or treatment decision-making. Overall, our findings identify candidate transcriptomic markers associated with PTC occurrence and lymph node metastasis and provide a basis for future translational evaluation.

This case highlights the diagnostic value of empiric high-dose radioiodine therapy combined with SPECT/CT in detecting occult metastases. Furthermore, the 11-year disease-free survival in our patient underscores that early identification and surgical resection of solitary brain metastases from PTC can lead to an exceptionally favorable long-term prognosis.

Despite multidisciplinary recommendations for completion thyroidectomy and contralateral adnexectomy, the patient declined further surgery, opting for clinical and biochemical surveillance alone. This case underscores the importance of managing malignant struma ovarii according to thyroid carcinoma protocols while respecting patient autonomy.

Our study provides valuable insights into TERT promoter-mutated TCs, broadening their recognized morphologic spectrum and highlighting the importance of incorporating such features into routine evaluation to improve risk stratification and better identify aggressive tumours.

These findings clarify the role of S100A10 and RAN in PTC progression and highlight their potential as therapeutic targets, linking EMT with PI3K/AKT signaling.

This study illustrates a novel mechanism of cytoskeletal proteins involvement in metabolic adaptation of drug-resistant thyroid cancer cells. The KRT15-KRT81-DGKB pathway is a promising therapeutic target, particularly in combination with lenvatinib, for refractory thyroid cancer patients.

Patients underwent thyroidectomy, selective postoperative radioactive iodine ablation, and levothyroxine suppression therapy...Despite their low prevalence, TPMs were independently associated with adverse oncological outcomes, including higher rates of recurrence and mortality. TPMs may serve as valuable prognostic markers for early risk stratification in PTC.

P=N/A, N=34, Not yet recruiting, University of Maryland, Baltimore